Group by Gene: Include preclinical: Chemotherapy CD Protein Inhibitors Immunotherapy Other RAR/RXR Epigenetics Interleukins PI3 Kinase Inhibitors Immune Checkpoint Inhibitors Tyrosine Kinase Inhibitors DNA | IL-2 stimulant denileukin diftitox | Retinoid X receptor modulator bexarotene oral | HDAC inhibitor vorinostat | PD1 inhibitor pembrolizumab | STAT3 protein degrader KT-333 | PD-L1 inhibitor durvalumab | Topoisomerase II inhibitor, DNA synthesis inhibitor gemcitabine + doxorubicin hydrochloride | CD70 inhibitor ARGX-110 | SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor RP6530 | CD30-targeted antibody-drug conjugate, Microtubule inhibitor brentuximab vedotin | TEQ102 | JAK1 inhibitor, JAK2 inhibitor ruxolitinib | TNFα inhibitor, PD-L1 inhibitor, IL-12 inhibitor, IL-6 inhibitor durvalumab + lenalidomide |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||
TNFRSF8 positive | |||||||||||||
TNFRSF8 expression | |||||||||||||
RPS6 underexpression | |||||||||||||
ICOS underexpression | |||||||||||||
PD-1 overexpression | |||||||||||||
CD70 expression | |||||||||||||
IL10-L | |||||||||||||
TNFA-L | |||||||||||||
CCL20-L | |||||||||||||
PD-L1 underexpression | |||||||||||||
IL2RA expression |